Intriguingly, GLP-1 analogues in combination with a monoclonal anti-interleukin-21 antibody may, in turn, be useful to delay disease progression of type 1 diabetes when therapy is initiated shortly after diagnosis15. Here, IL21 is linked to type 1 diabetes mellitus.